Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Aged
Antibodies, Monoclonal, Humanized
/ administration & dosage
Biomarkers, Tumor
/ genetics
Carcinoma, Transitional Cell
/ drug therapy
DNA Repair
/ drug effects
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Male
Middle Aged
Neoadjuvant Therapy
/ adverse effects
Neoplasm Invasiveness
/ genetics
Transcriptome
/ genetics
Transforming Growth Factor beta
/ genetics
Urologic Neoplasms
/ drug therapy
Urothelium
/ drug effects
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
24
06
2019
accepted:
25
09
2019
pubmed:
7
11
2019
medline:
21
1
2020
entrez:
6
11
2019
Statut:
ppublish
Résumé
Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers
Identifiants
pubmed: 31686036
doi: 10.1038/s41591-019-0628-7
pii: 10.1038/s41591-019-0628-7
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biomarkers, Tumor
0
Transforming Growth Factor beta
0
atezolizumab
52CMI0WC3Y
Banques de données
ClinicalTrials.gov
['NCT02662309']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1706-1714Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Type : ErratumIn
Références
Bellmunt, J., Powles, T. & Vogelzang, N. J. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat. Rev. 54, 58–67 (2017).
doi: 10.1016/j.ctrv.2017.01.007
Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748–757 (2018).
doi: 10.1016/S0140-6736(17)33297-X
Mariathasan, S. et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
doi: 10.1038/nature25501
Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24, 1655–1661 (2018).
doi: 10.1038/s41591-018-0198-0
Necchi, A. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol. 36, 3353–3360 (2018).
doi: 10.1200/JCO.18.01148
Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477–486 (2019).
doi: 10.1038/s41591-018-0337-7
Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 24, 1649–1654 (2018).
doi: 10.1038/s41591-018-0197-1
Reardon, Z. D. et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur. Urol. 67, 165–170 (2015).
doi: 10.1016/j.eururo.2014.01.009
International Collaboration of Trialists et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171–2177 (2011).
doi: 10.1200/JCO.2010.32.3139
Kim, H. S., Jeong, C. W., Kwak, C., Kim, H. H. & Ku, J. H. Pathological T0 following cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer: a network meta-analysis. Clin. Cancer Res. 22, 1086–1094 (2016).
doi: 10.1158/1078-0432.CCR-15-1208
Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976–1986 (2018).
doi: 10.1056/NEJMoa1716078
Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454–461 (2019).
doi: 10.1038/s41591-019-0357-y
Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).
doi: 10.1016/S0140-6736(16)00561-4
Nowacki, T. M. et al. Granzyme B production distinguishes recently activated CD8
doi: 10.1016/j.cellimm.2007.07.004
Powles, T. et al. Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study. J. Clin. Oncol. 36, 409–409 (2018).
doi: 10.1200/JCO.2018.36.6_suppl.409
Teo, M. Y. et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J. Clin. Oncol. 36, 1685–1694 (2018).
doi: 10.1200/JCO.2017.75.7740
Wynn, T. A. & Ramalingam, T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18, 1028–1040 (2012).
doi: 10.1038/nm.2807
Richards, K. E. et al. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene 36, 1770–1778 (2017).
doi: 10.1038/onc.2016.353
Sjodahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377–3386 (2012).
doi: 10.1158/1078-0432.CCR-12-0077-T
Warrick, J. I. et al. Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur. Urol. 75, 18–22 (2019).
doi: 10.1016/j.eururo.2018.09.003
Sun, L. et al. WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy. Oncoimmunology 7, e1488359 (2018).
doi: 10.1080/2162402X.2018.1488359
Bahleda, R. et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin. Cancer Res. 25, 4888–4897 (2019).
doi: 10.1158/1078-0432.CCR-18-3334
Nassar, A. H. et al. Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites. Clin. Cancer Res. 25, 2458–2470 (2019).
doi: 10.1158/1078-0432.CCR-18-3147
Loriot, Y. et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 381, 338–348 (2019).
doi: 10.1056/NEJMoa1817323
A’Hern, R. P. Sample size tables for exact single-stage phase II designs. Stat. Med. 20, 859–866 (2001).
doi: 10.1002/sim.721